☆ 4.7 Article

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody

Xinyu Song et al.

Summary: This study explored the intratumoral heterogeneity and sought prognostic biomarkers for immunotherapy efficacy using digital spatial profiling. The findings showed that genetic information from the stromal region can better predict the efficacy of bispecific antibody treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Oncology

Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?

Riccardo Carloni et al.

Summary: Hepatocellular carcinoma is a common cause of cancer-related death, and most patients are diagnosed with advanced disease or experience recurrence after surgery. Immunotherapy, specifically the combination of two immune checkpoint inhibitors, has shown potential in other solid tumors and is now being explored for HCC.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M. O'Malley et al.

Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares et al.

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi et al.

Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.

MOLECULAR CANCER (2022)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Bispecific antibodies in oncology

Arman Esfandiari et al.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Review Oncology

Early-Phase Oncology Trials: Why So Many Designs?

Matthieu Clertant

Summary: Over the past 30 years, statisticians have made considerable efforts to improve the design and accuracy of early-phase oncology trials. However, clinicians have shown some reluctance to fully embrace more efficient model-based approaches, possibly due to the difficulty in understanding the advantages offered by these modern designs. This study reviews 15 currently proposed and used designs, highlighting their properties and differences, and emphasizing the need for ad hoc modifications in certain designs to ensure satisfactory performance.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3trial

Shun Lu et al.

Summary: The study evaluated the efficacy and safety of sintilimab with or without IBI305, combined with pemetrexed and cisplatin, for treating EGFR mutated non-small-cell lung cancer patients. The interim analysis showed prolonged progression-free survival in patients treated with sintilimab plus IBI305 plus chemotherapy compared to chemotherapy alone.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Cadonilimab: First Approval

Susan J. Keam

Summary: Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, has been approved for the treatment of relapsed or metastatic cervical cancer in China. It is also being developed for other solid tumors such as lung cancer and gastric cancer. This article provides an overview of the milestones in the development of Cadonilimab for the treatment of patients with relapsed or metastatic cervical cancer.

DRUGS (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

R. Perets et al.

Summary: The study investigated the combination therapy of the novel anti-CTLA-4 antibody Quavonlimab with pembrolizumab in patients with advanced solid tumors and NSCLC, focusing on safety, tolerability, and efficacy. Results showed that Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile compared to other dosing schedules.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

添加到收藏夹

Article Oncology

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng-Hua Wang et al.

Summary: The study evaluated the antitumor activity and safety of toripalimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) refractory to standard chemotherapy, demonstrating a manageable safety profile and durable clinical response. Early decrease in plasma EBV DNA copy number was correlated with favorable response, indicating potential as a biomarker for treatment efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Yunpeng Yang et al.

Summary: The study evaluated the antitumor activity of camrelizumab in patients with recurrent or metastatic NPC and found that patients with high MHC-II+ cell density and PD-L1 expression were more likely to benefit from the drug.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson et al.

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Bispecific Antibodies to PD-1 and cTLA4: Doubling Down on T cells to Decouple efficacy from Toxicity

Elizabeth M. Burton et al.

Summary: MEDI5752 is a bispecific anti-PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells. The development of this antibody aims to increase efficacy and potentially minimize toxicity.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue

Edwin Roger Parra et al.

Summary: The study optimized five mIF panels for immuno-profiling tumor tissues, identifying correlations between B7-H4 and OX40 expression with malignant cells and revealing an immunosuppressive microenvironment.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4

Chunjuan Jiang et al.

Summary: The development of a novel smart agent KN046@F-19-ZIF-8 improves the immune response rate of antibody drugs in tumor treatment and reduces toxic side effects, achieving excellent antitumor efficacy.

ADVANCED SCIENCE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1

Yulia Vugmeyster et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Biochemical Research Methods

Bispecific antibodies in cancer immunotherapy

Christoph Rader

CURRENT OPINION IN BIOTECHNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Jianjun Gao et al.

NATURE MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

Jermaine Coward et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

Patricia Gaule et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Using Model-Based Learn and Confirm to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial

J. Elassaiss-Schaap et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

添加到收藏夹

Article Oncology

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Hidehito Horinouchi et al.

INVESTIGATIONAL NEW DRUGS (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3+3 Design for Practical Phase I Trials

Yuan Ji et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.